MRCPUK SEND

Once your order is placed, your SEND practice questions reach your inbox within a minute — no shipping, no waiting around. Dumpkiller designed the whole MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) preparation experience around getting you studying today, with 200 questions ready on any device.

MRCPUK SEND Exam Overview:

MRCPUK SEND Exam Syllabus Topics:

What Candidates Ask About the MRCPUK SEND Exam

Can you give me an overview of the SEND exam?

The MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) exam (code: SEND) is the official MRCPUK exam that leads to the MRCPUK Certification certification. It sits at the Specialty Certificate level of the MRCPUK certification track. It is also connected with related credentials such as Specialty Certificate in Endocrinology and Diabetes (SCE). Passing it proves to employers that your skills have been validated by MRCPUK itself, which is why the SEND credential keeps showing up in job postings.

How many questions are in the SEND exam, and how long does it take?

The MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) exam gives you 360 minutes to work through 200. Pacing matters more than most candidates expect, so before exam day, run at least one full timed session in the Dumpkiller test engine to learn how long you can afford per question. If an item stalls you, flag it and move on — coming back later beats burning five minutes on a single question.

Are there any prerequisites for the SEND exam?

According to MRCPUK, the following applies: There are no formal entry requirements, although UK trainees typically sit the examination in their penultimate year of specialty training.. Certification policies do change from time to time, so confirm the latest requirements on the official exam page at https://www.thefederation.uk/examinations/specialty-certificate-examinations/specialties/endocrinology-and-diabetes before you register.

Can I try the SEND practice questions before buying?

Yes. Dumpkiller offers a free SEND PDF demo so you can review the question style, difficulty, and explanations before committing to anything. After purchase, your MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) material includes 365 days of free updates, and if your product expires after that, you can extend the update service at a 50% discount from your member zone.

What happens if I do not pass the SEND exam, and how is my order delivered?

If you take the corresponding SEND exam within 60 days of your purchase and do not pass, you can apply for a full refund under our 100% Money Back Guarantee, subject to a few conditions: the failed exam must be the one matching your purchase; sitting the exam within 3 days of purchase does not qualify, since that leaves too little preparation time; downloading the material without actually taking the exam does not qualify; free materials and expired orders are excluded; and the candidate name must match the payer name. To apply, send a scanned copy of your enrollment slip together with your official Score Report (PDF) within 2 days after the exam, and claims are processed within 7 days. If you would rather not take a refund, you can exchange your purchase for two free products of equal value while keeping the update service on the product you originally bought. As for delivery, everything is an instant download: your products are sent to your email within one minute of payment — contact customer service if nothing arrives within 2 hours — and there is no limit on the number of computers you can install the software on.

What topics are covered in the SEND exam?

The official MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) syllabus is organized into 7 main domains. The first three are Thyroid Disorders, Reproductive Endocrinology, and Calcium and Bone Metabolism. For the full domain-by-domain breakdown, see the complete Exam Topics outline above.

MRCPUK Endocrinology and Diabetes (Specialty Certificate Examination) Sample Questions:

Question #1

A 48-year-old man was referred by his general practitioner, whose letter stated: 'Please review this man's blood pressure management, as he has requested a second opinion, having seen information on the internet about the need for more detailed investigation. He has been having treatment for 10 years.'
At the consultation, the patient confirmed that he was currently taking bendroflumethiazide
2.5 mg daily, atenolol 50 mg daily and perindopril 8 mg daily. His clinic blood pressure was 169/108 mmHg. Clinical examination was otherwise normal.
Investigations:
serum sodium142 mmol/L (137-144)
serum potassium3.9 mmol/L (3.5-4.9)
estimated glomerular filtration rate (MDRD)>60 mL/min/1.73 m2 (>60)
ambulant plasma renin activity0.5 pmol/mL/h (3.0-4.3)
ambulant plasma aldosterone380 pmol/L (330-830)
What is the most appropriate next step in management?

A. withdraw atenolol and repeat renin and aldosterone
B. add amlodipine
C. CT scan of adrenal glands
D. urine steroid profile
E. fludrocortisone suppression test

Question #2

A 52-year-old woman was referred to the clinic having lost 3-4 kg in weight over the previous 3 months. She also had palpitations and a sense of tremulousness. A diagnosis of thyrotoxicosis was confirmed by a blood test arranged by her general practitioner (GP).
Investigations (arranged by GP):
serum thyroid-stimulating hormone<0.01 mU/L (0.4-5.0)
serum free T435.8 pmol/L (10.0-22.0)
serum free T310.0 pmol/L (3.0-7.0)
On examination at her first clinic visit, she had a fine tremor, her pulse was 92 beats per minute and regular, and her eyes appeared normal. Her right thyroid lobe was moderately enlarged, and her left lobe was normal on examination. There was no associated lymphadenopathy. A technetium-99m thyroid isotope uptake scan was arranged (see image).

What is the most likely cause of her thyrotoxicosis?

A. de Quervain's thyroiditis
B. factitious thyrotoxicosis
C. Graves' disease
D. toxic thyroid adenoma
E. toxic multinodular goitre

Question #3

A 70-year-old man was admitted after the gradual development of confusion. He had no
significant medical history.
Examination was otherwise normal.
Investigations:
serum sodium110 mmol/L (137-144)
serum potassium3.8 mmol/L (3.5-4.9)
serum creatinine50 umol/L (60-110)
He was treated with several litres of sodium chloride 0.9% over the subsequent few days, resulting in a rapid restoration of serum sodium to the normal range. This coincided with the development of limb weakness and spasticity that became permanent.
The movement of what substance(s) between the intracellular fluid compartment (ICF) and extracellular fluid compartment (ECF) explains the changes in this patient?

A. sodium and water from ECF to ICF
B. water from ICF to ECF
C. sodium from ICF to ECF
D. water from ECF to ICF
E. sodium from ECF to ICF

Question #4

A 16-year-old girl presented with primary amenorrhoea. In early childhood she had undergone an inguinal herniorrhaphy. She had no other medical history of note. There was a family history of infertility affecting a maternal aunt.
On examination, she had adult breast development but no pubic or axillary hair. Examination was otherwise normal.
What test is most likely to aid diagnosis?

A. ovarian antibody titres
B. blood karyotype
C. MR scan of pituitary and olfactory bulbs
D. plasma gonadotropins
E. ultrasound scan of pelvis

Question #5

A 40-year-old man presented with a 4-month history of increasing central obesity. His medical history included HIV infection and allergic rhinitis. He was taking highly active antiretroviral therapy and nasal fluticasone.
On examination, he had marked central adiposity. His blood pressure was 160/95 mmHg.
Investigations:
serum sodium140 mmol/L (137-144)
serum potassium3.8 mmol/L (3.5-4.9)
serum cholesterol5.5 mmol/L (<5.2)
fasting serum triglycerides8.20 mmol/L (0.45-1.69)
serum cortisol (09.00 h)<50 nmol/L (200-700)
serum thyroid-stimulating hormone4.6 mU/L (0.4-5.0)
serum free T49.3 pmol/L (10.0-22.0)
What is the most likely diagnosis?

A. hypothyroidism
B. Addison's disease
C. Cushing's syndrome
D. HIV-associated lipodystrophy
E. glucocorticoid resistance

Solutions: